What is HaystackMRD?
Founded in 2021, HaystackMRD operates at the intersection of biotechnology and clinical oncology. The company is dedicated to the development of sophisticated monitoring solutions that detect minimal residual disease, a critical factor in determining the efficacy of cancer therapies. By providing actionable insights into patient response, HaystackMRD is effectively bridging the gap between laboratory research and bedside application. Its market position is bolstered by a robust intellectual property portfolio and a clear focus on high-impact diagnostic tools that address the unmet needs of oncologists and patients alike.
How much funding has HaystackMRD raised?
HaystackMRD has raised a total of $56M across 1 funding round:
Series A
$56M
Series A (2022): $56M with participation from Bruker, Alexandria Venture Investments, Exact Ventures, and Catalio Capital Management
Key Investors in HaystackMRD
Bruker
Bruker Corporation is a global leader in scientific instrumentation and diagnostic solutions, providing advanced analytical technologies that support pharmaceutical and clinical research worldwide.
Catalio Capital Management
Catalio Capital Management is a New York-based firm specializing in breakthrough biomedical technology, leveraging a deep network of venture partners to scale category-defining healthcare companies.
Exact Ventures
Exact Ventures is an independent market intelligence firm that provides critical advisory services and benchmarking to help technology companies navigate complex market transitions.
What's next for HaystackMRD?
With the recent influx of capital, HaystackMRD is poised to transition from its initial development phase into a period of aggressive commercial scaling and clinical validation. The company's roadmap includes the expansion of its diagnostic pipeline and the strengthening of its strategic partnerships with global healthcare providers. As the oncology sector continues to shift toward data-driven, personalized care, HaystackMRD is well-positioned to become a cornerstone of modern therapy monitoring. Future growth will likely focus on regulatory milestones and the integration of its technology into standard-of-care protocols, further cementing its role as a leader in the molecular diagnostics space.
See full HaystackMRD company page
